New YouTube videos detected. Observed at http://www.youtube.com/user/MPNUniversity Vosaroxin and Decitabine in Newly Diagnosed Older Patients with AML and High Risk MDS Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks Combination of Oral Rigosertib and Azacitidine in Patients with MDS HRQoL and Efficacy in the Phase III Persist-1 Trial of Pacritinib Vs BAT Quazartinib Significantly Improves OS in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Phase 3 Study Peripheral T-Cell Lymphoma: Alisertib Versus Investigator’s Choice 5-Azacytidine in Combination with Ruxolitinib As Therapy for Patients with MDS/MPN Impact of Eltrombopag in Refractory Aplastic Anemia Sorafenib to Chemotherapy Improves the OS in Older Adults with FLT3-ITD Mutated AML Molecular Mutations in AML and MDS: Adverse Impact of TET2 Safety of Lenalidomide 10mg in Non-Del(5g) Versus Del(5g) in Patients with Lower-Risk MDS SGN-CD33A as Monotherapy in patients with CD33-Positive Acute Myeloid Leukemia (AML) SGN-CD33A Plus Hypomethylating in frontline Unfit AML patients Redirecting to this page Note: The design you were just viewing was captured on a day in the past. The design of this page might have changed since then, and it might look different on different devices. Continue to the page. Don't show me this message again. Out-Market Your Competitors? Get complete competitive insights on over 2.2 million companies to drive your marketing strategy. Create Free Account Log in Out-Market Your Competitors Get complete competitive insights on over 2.2 million companies to drive your marketing strategy. Create Free Account Create Free Account Sign up with Linkedin Sign up with Facebook Already a user? Log in Out-Market Your Competitors Create a free account to get complete competitive insights on over 2.2 million companies. Create Free Account Already a user? Log in.